Maternal Health Therapeutics Market Revenue to Attain USD 9.64 Bn by 2035

Published: 04 Feb 2026

Author: Precedence Research

Share:

Maternal Health Therapeutics Market Revenue and Trends 2026 to 2035

The global maternal health therapeutics market revenue was valued at USD 4.72 billion in 2025 and is expected to attain around USD 9.64 billion by 2035, growing at a CAGR of 7.40% during forecast period.This market is experiencing unprecedented growth, driven by the increasing prevalence of pregnancy-related health disorders.

What Factors Drive the Maternal Health Therapeutics Market?

The growing demand for postpartum depression (PPD) treatments and mental health support is the major driver, accelerating the growth of the maternal health therapeutics market during the forecast period. The market’s growth is also supported by the rapid expansion of telehealth services and rising government initiatives for maternal care to reduce maternal mortality.

Segment Insights

• By therapeutic category, the oxytocics & uterotonics segment held the largest market share of nearly 24% in 2025. As the postpartum hemorrhage is a leading cause of maternal mortality, the use of these drugs is highly effective in preventing and treating it. Oxytocin and uterotonics are used as first-line interventions during childbirth and emergencies, making them widely adopted in hospitals and maternity clinics.
• By indication, the postpartum hemorrhage segment led the market, accounting for an estimated 46% share in 2025, owing to the increasing cases of postpartum hemorrhage (PPH). The increasing prevalence of high-risk pregnancies and increasing C-section rates spurs the demand for postpartum hemorrhage (PPH) therapeutics.
• By route of administration, the injectables segment contributed the biggest market share of nearly 46% in 2025. Injections serve as the first-line treatment owing to their rapid therapeutic action and prevent postpartum hemorrhage. In addition, the introduction of pre-filled syringes and long-acting injectables has simplified patient care during pregnancy complications.
• By distribution channel, the hospital pharmacies segment accounted for the majority of the market share, nearly 52% in 2025. Hospital pharmacies are the dominant distribution channel in the maternal health therapeutics market. Hospital pharmacies play a crucial role in providing immediate and specialized care for maternal health issues.

Regional Insights

North America held the dominant share of the maternal health therapeutics market in 2025. The region’s leadership is driven by the presence of sophisticated healthcare infrastructure, increasing prevalence of postpartum disorders, rise of telemedicine and remote monitoring, surge in R&D funding, supportive government programs targeting reduced maternal mortality rates, and a rise in FDA-approved rapid-acting antidepressants for the treatment of postpartum depression. Such a combination of factors is likely to fuel the expansion of the region in the coming years.

• In January 2026, Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, announced that enrollment and participant dosing had been completed in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).
• On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The growth of the region is attributed to the rise in the maternal population, increasing awareness of prenatal/postnatal care, improved diagnostic infrastructure, growing demand for telehealth services, growing demand for mental health treatments post-pregnancy, such as postpartum depression and anxiety therapies, and government-backed maternal mental health initiatives.

Maternal Health Therapeutics Market Coverage

Recent Developments

• In September 2025, Biogen Inc. announced that the European Commission (EC) had granted marketing authorization for ZURZUVAE (zuranolone) to treat post-partum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, oral, 14-day treatment which represents a novel therapeutic approach, offering the first and only treatment indicated for PPD in the E.U. This approval is a major milestone in addressing a critical unmet need in maternal health for women in Europe. (Source: https://investors.biogen.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7533

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344